KZR Stock Summary and Trading Ideas (Kezar Life Sciences | NASDAQ:KZR)

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Kezar Life Sciences trades on the NASDAQ stock market under the symbol KZR.

As of January 2, 2026, KZR stock price was flat at $6.29 with 6,549 million shares trading.

KZR has a beta of 0.86, meaning it tends to be less sensitive to market movements. KZR has a correlation of 0.07 to the broad based SPY ETF.

KZR has a market cap of $46.06 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, KZR traded as high as $74.40 and as low as $3.53.

The top ETF exchange traded funds that KZR belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DCOR.

KZR has underperformed the market in the last year with a price return of -6.4% while the SPY ETF gained +17.8%. However, in the short term, KZR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +61.3% vs +2.8% return in SPY. But in the last 2 weeks, KZR shares have been beat by the market, returning +0.5% compared to an SPY return of +2.0%.

KZR support price is $6.20 and resistance is $6.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KZR shares will trade within this expected range on the day.